

Information For the Use of
Empagliflozin (25mg) + Linagliptin (5mg) Tablet

Emplozin L 25/5 Tablet

Brand Name: Emplozin L 25/5 Tablet

Dosage Form: Tablet

Composition:

Each film-coated tablet contains:

- Empagliflozin IP 25 mg
 - Linagliptin IP 5 mg
-

Description:

Emplozin L 25/5 Tablet is a fixed-dose combination of Empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. It is indicated for the management of type 2 diabetes mellitus in adults inadequately controlled with diet, exercise, or monotherapy. It helps in improving glycemic control through complementary mechanisms of action, reducing both fasting and post-prandial blood glucose levels.

Indications:

Indicated for the treatment of:

- Type 2 diabetes mellitus
- Patients inadequately controlled on Empagliflozin or Linagliptin monotherapy
- Adjunct to diet and exercise for glycemic control

It helps in achieving effective blood glucose management and reducing the risk of long-term diabetic complications.

Dosage & Administration:

Dosage should be as directed by the physician.

The tablet may be taken with or without food.

Regular monitoring of blood glucose levels and renal function is recommended during therapy.

Pharmacological Action:

- Empagliflozin inhibits SGLT2 in the proximal renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion.
- Linagliptin inhibits the DPP-4 enzyme, resulting in increased levels of incretin hormones, which enhance glucose-dependent insulin secretion and reduce glucagon secretion.

Together, these mechanisms provide synergistic glycemic control without significant risk of hypoglycemia when used alone.

Side Effects:

Common side effects include urinary tract infections, genital fungal infections, increased urination, nasopharyngitis, headache, and mild gastrointestinal discomfort.

Rarely, dehydration, hypersensitivity reactions, pancreatitis, or diabetic ketoacidosis may occur.

Precautions & Warnings:

- Monitor renal function before and during treatment
- Use with caution in elderly patients and those at risk of dehydration
- Observe for signs of urinary tract or genital infections
- Monitor for symptoms suggestive of pancreatitis

- Not indicated for type 1 diabetes mellitus or diabetic ketoacidosis
-

Drug Interactions:

May interact with diuretics, insulin, and other antidiabetic agents, increasing the risk of hypoglycemia or volume depletion.

Caution is advised with medications affecting renal function.

Storage:

Store below 25°C in a cool, dry place.

Protect from moisture and light.

Keep out of reach of children.

Manufactured in India for:



Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I, Panchkula-134113

Corporate Office :

Plot no. 307, Industrial Area Phase-2,

Panchkula, Haryana -134113

TM: Trademark Applied for